Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

Mooi instap moment Dendreon

1.743 Posts
Pagina: «« 1 ... 70 71 72 73 74 ... 88 »» | Laatste | Omlaag ↓
  1. [verwijderd] 7 juni 2007 16:13

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Jommeke schreef:

    Shareholder Class Action Filed Against Dendreon Corporation by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP

    biz.yahoo.com/prnews/070606/new128.ht...
    amerikanen hebben zeker niets beters te doen.
    tegen ieder bedrijf loopt wel een class action or what-so-ever. vermoeiend volkje.

    ik vond t er zo gezellig in 1986, toen ik door 23 staten toerde met mn oude chevy.
  7. [verwijderd] 3 juli 2007 15:54

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    kijk, dit aandeel is heel wat spannender dan die renteloze obligatie die gtcb heet.

    dollartje erbij op 8.

    7.5 miljoen verhandeld reeds, zeg maar 60 miljoen.

    vraag aan de kenners: zat er op die lening die kort geleden is uitgegeven voor 6 dollar ook een lock up periode?

    mvg
  8. [verwijderd] 3 juli 2007 16:04

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    connect schreef:

    kijk, dit aandeel is heel wat spannender dan die renteloze obligatie die gtcb heet.

    dollartje erbij op 8.

    7.5 miljoen verhandeld reeds, zeg maar 60 miljoen.

    vraag aan de kenners: zat er op die lening die kort geleden is uitgegeven voor 6 dollar ook een lock up periode?

    mvg
    The rocket stocks on this week's list fit each of these criteria.

    First up is Dendreon (DNDN - Cramer's Take - Stockpickr - Rating), a biotech company that recently has seen a huge amount of call buying in its July $7.50 and the July $10 options. On Wednesday more than 120,000 contracts were traded and more than 100,000 of them where call-buys for both in-the-money and out-of-the-money July calls.

    You don't buy that amount of calls on a $7.40 stock because you think it's a good investment; the investors that make that kind of bet do so because they believe something is going to happen, and happen soon.

    Dendreon is a violent stock that has been known to move as much as 40%-50% in one trading day. For more stocks that have unusual option activity, check out and bookmark Stocks With Unusual Options Activity, a portfolio we update daily. Other stocks on this list recently include JDSU (JDSU - Cramer's Take - Stockpickr - Rating) and General Motors (GM - Cramer's Take - Stockpickr - Rating).

  13. [verwijderd] 11 juli 2007 15:54

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    SEC launches informal probe into Dendreon

    By Val Brickates Kennedy, MarketWatch
    Last Update: 9:32 AM ET Jul 11, 2007

    BOSTON (MarketWatch) -- The Securities and Exchange Commission has launched an informal probe into Dendreon Corp.'s handling of its prostate cancer drug Provenge, which recently failed to win approval from the Food and Drug Administration.
    In a filing made Tuesday, Dendreon said it was notified on July 9 that the SEC is probing clinical trials for Provenge, its market application for the drug and the FDA's subsequent review of that application.
    The company added, "The SEC's letter notes that the request should not be construed as any indication by the SEC or its staff that a violation of the federal securities laws has occurred nor should it be considered a reflection upon any person, entity or security."
    Dendreon said it has also been accused by a shareholder of wrongful disclosure and insider trading in regards to its dealings with the FDA in early 2007 over Provenge.
    The shareholder also has requested the company's board investigate certain officers and directors. The board is "evaluating a response" to the letter, the company said.
    Dendreon said it intends to fully cooperate with the SEC and will not comment further on the matter until the investigation is completed.
    Dendreon's stock price has zigzagged sharply over the past year in reaction to news surrounding its market application for Provenge. If approved, Provenge would be the company's first product on the market.
    In late March, the stock rocketed almost 150% after an FDA advisory panel gave Provenge the thumbs up. Then, in early May, Dendreon shares sank over 60% on word that the FDA would not approve Provenge unless the company provided more clinical data demonstrating its efficacy in treating prostate cancer.
    Later, on May 31, Dendreon shares rebounded dramatically, soaring over 90% on news that the FDA might not require an additional clinical trial.
    Val Brickates Kennedy is a reporter for MarketWatch in Boston.
  16. [verwijderd] 11 augustus 2007 00:12

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    na een meer dan rampzalige week op de wereldbeurzen heeft dendreon zich toch aardig weten te handhaven op bovenstaand nivo.

    mvg, kopje troost
  17. [verwijderd] 18 augustus 2007 00:23

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Slot: 7.32

    Na beurs, op dit moment: 8.85 (00.22 uur)

    Omdat:

    Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients

    SEATTLE, August 17, 2007 - Dendreon Corporation (Nasdaq: DNDN) today announced publication of results from a Phase 1 study of NEUVENGE, an investigational active cellular immunotherapy, in the August 20 issue of the Journal of Clinical Oncology. The article highlights the safety profile, immune response and clinical activity of NEUVENGE in women with HER2/neu-positive breast cancer who have failed standard therapy.

    "In addition to demonstrating that NEUVENGE was safe and well tolerated, the T-cell responses seen in these patients and the prolonged disease stabilization in the absence of other anti-cancer therapies in many patients is promising," said John W. Park, M.D., associate clinical professor of medicine and neurosurgery at the University of California, San Francisco and lead author of the publication. "These observations are encouraging and are suggestive of the clinical benefit of NEUVENGE, particularly in light of the aggressive cancer seen in these patients who had progressed while on standard therapy. The findings warrant additional studies of NEUVENGE for the many women with advanced breast cancer who have exhausted many of their treatment options."

    Study Design

    The Phase 1 study (D2000-2) was conducted to evaluate the safety and immunologic activity of NEUVENGE in patients with HER2-overexpressing metastatic breast cancer who had failed standard therapy, including prior treatment with chemotherapy and trastuzumab. All patients had experienced disease progression while on standard therapy. There were 19 patients enrolled in the study with 18 patients receiving treatment with NEUVENGE. Patients underwent three infusions of NEUVENGE at Weeks 0, 2, and 4 following randomization. Patients who achieved a partial response, or had stable disease lasting through Week 52, were eligible for re-treatment, a booster, using the same protocol and dose as the initial treatment. Endpoints included safety, immunologic activity and antitumor activity.

    Study Results

    Treatment with NEUVENGE was generally well tolerated. The majority of side effects were mild, including infusion-related fever and chills that were usually of low grade and typically lasted for one to two days following infusion. No patient discontinued the trial because of toxicity.

    Treatment with NEUVENGE stimulated significant immune responses, which were shown to be enhanced following booster infusions. Twenty-two percent of patients had evidence of anti-cancer activity. This included one patient who experienced a partial response lasting approximately 6 months and three patients who had stable disease for over a year (74.9-94.0 weeks) without the addition of any other cancer therapy other than the continuation of bisphonates. Two additional patients had stable disease for up to 20 weeks. The study concluded that NEUVENGE was feasible, well-tolerated and showed evidence of anti-cancer activity.

    "We are pleased that the results from this Phase I study of NEUVENGE demonstrate its potential as a treatment for advanced breast cancer patients," said Mark Frohlich, M.D., vice president of clinical affairs at Dendreon. "These data, together with the data we have published on the use of Provenge(R) (sipuleucel-T) in prostate cancer, further substantiate the promise of active cellular immunotherapies as new treatments for different types of cancer."

    P.
  18. [verwijderd] 18 augustus 2007 01:02

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    psycho-pharma schreef:

    Slot: 7.32

    Na beurs, op dit moment: 8.85 (00.22 uur)

    Omdat:

    Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients

    'tja, psycho,
    daar kunnen we bij GTCb alleen maar van dromen,
    was zelfs ff boven de $9.
    Ik kan er nog steeds niet bij waarom je niet
    aan $20-25 verkocht hebt,
    het was tenslotte maal vier,
    maal vijf, misschien zelfs wel maal zes?
    Natuurlijk, blijft het een eigen beslissing.
    Het ga je goed!

  19. [verwijderd] 18 augustus 2007 08:01

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    SkySpam1 schreef:

    [quote=psycho-pharma]
    Slot: 7.32

    Na beurs, op dit moment: 8.85 (00.22 uur)

    Omdat:

    Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients

    [/quote]

    'tja, psycho,
    daar kunnen we bij GTCb alleen maar van dromen,
    was zelfs ff boven de $9.
    Ik kan er nog steeds niet bij waarom je niet
    aan $20-25 verkocht hebt,
    het was tenslotte maal vier,
    maal vijf, misschien zelfs wel maal zes?
    Natuurlijk, blijft het een eigen beslissing.
    Het ga je goed!

    Inderdaad, daar zou ik echt nog steeds ziek van zijn! Wat een winst had je daar kunnen pakken! Het gevaar van beleggen, te gretig worden!
1.743 Posts
Pagina: «« 1 ... 70 71 72 73 74 ... 88 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.481
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.200
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.525
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.647
Aedifica 3 901
Aegon 3.258 322.654
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.885
Agfa-Gevaert 14 2.048
Ahold 3.538 74.292
Air France - KLM 1.025 34.996
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.330
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.813
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.719
AMG 971 133.057
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 485
Antonov 22.632 153.605
Aperam 92 14.921
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.572
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.716
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.079
ASML 1.766 106.012
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 469
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.610
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390

Macro & Bedrijfsagenda

  1. 07 februari

    1. Aperam Q4-cijfers
    2. Orange Belgium Q4-cijfers
    3. Crédit Agricole Q4-cijfers (Fra)
    4. TotalEnergies Q4-cijfers (Fra)
    5. Novo Nordisk Q4-cijfers (Dee)
    6. Industriële productie december (Dld)
    7. Handelsbalans december (Dld)
    8. Harley-Davidson Q4-cijfers (VS)
    9. Banengroei en werkloosheid januari (VS) Banengroei: 170K, werkloosheid: 4,1%, uurlonen: +3,8% YoY volitaliteit verwacht
    10. Consumentenvertrouwen (Universiteit v Michigan) februari vlpg (VS)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda